This invention describes a process for the production of ANHYDROUS active pharmaceutical ingredients (APIs); a process for the preparation of HYDRATED active pharmaceutical ingredients, a process for the preparation of sterile and stable injectable solutions, and their use, more specifically, APIs which are taxane derivatives, especially (2R,3S) 4-acetoxy-2-α-benzoyloxy-5β-20-epoxy-1,7-β-10-β-tri-hydroxy-9-oxo-tax-11-en-13α-il 3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate (I); 4-acetoxy-2-α-benzoyloxy-5-β-20-epoxy-1, 7β-10-β-tri-hidroxy-9-oxo-tax-11-en-13α-il (2R,3S) 3-benzoylamino-2-hydroxy-3-phenylpropionate (II), and particularly 4-acetoxy-2-α-benzoyloxy-5β-20-epoxy-1, 7-β-10-β-tri-hidroxy-9-oxo-tax-11-en-13α-il (2R,3S) 3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate tri-hydrate (III).
这项发明描述了一种用于生产无
水活性药物成分(A
PI)的过程;一种用于制备
水合活性药物成分的过程,一种用于制备无菌稳定注射溶液的过程,以及它们的使用,更具体地说,是納烷衍
生物的A
PI,特别是(2R,3S)4-乙酰氧基-2-α-苯甲酰氧基-5β-20-环氧-1,7-β-10-β-三羟基-9-酮-11-烯-13α-基-3-叔丁氧羰基
氨基-2-羟基-
3-苯基丙酸酯(I);4-乙酰氧基-2-α-苯甲酰氧基-5-β-20-环氧-1,7β-10-β-三羟基-9-酮-11-烯-13α-基(2R,3S)3-苯甲酰
氨基-2-羟基-
3-苯基丙酸酯(II),特别是4-乙酰氧基-2-α-苯甲酰氧基-5β-20-环氧-1,7-β-10-β-三羟基-9-酮-11-烯-13α-基(2R,3S)3-叔丁氧羰基
氨基-2-羟基-
3-苯基丙酸酯三
水合物(III)。